Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05717998 · ClinicalTrials.gov registry record

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

A clinical trial of Lung Non-Small Cell Carcinoma and GastroEsophageal Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
28
Enrollment target
1
Study location

NCT05717998 is a study of Lung Non-Small Cell Carcinoma and GastroEsophageal Cancer that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 28 participants, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05717998, a study of Lung Non-Small Cell Carcinoma and GastroEsophageal Cancer, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
28 participants
Enrollment target
1
Study location

Study Summary

This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers. This study determines if any changes in the heart muscle can be detected either during the course of radiation therapy or shortly thereafter using specialized imaging techniques or blood tests. Cardiac magnetic resonance imaging may be used to help provide information about changes in the heart structure and function following radiation therapy. Positron emission tomography looks at differences in how the heart takes up radioactive sugar which is injected into the vein to assess changes in heart function following radiation therapy. This study may help identify patients at risk of heart issues following radiation therapy to the chest and ultimately help in the development of more effective and safe treatments for cancer in the future.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • PROCEDURE Magnetic Resonance Imaging of the Heart

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-04-02
Est. Completion 2026-06-18

What the Registry Record Tells You About NCT05717998

The ClinicalTrials.gov registry entry for NCT05717998 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (82% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT05717998 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05717998 about?

NCT05717998 is a clinical study titled "Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy". This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers. This study determines if any changes in the heart muscle can be detected eith...

What is the current status of trial NCT05717998?

This trial is currently active not recruiting. The enrollment target is 28 participants. The study started on 2021-04-02. Estimated completion is 2026-06-18.

What conditions does trial NCT05717998 study?

This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer.

What interventions are being tested in trial NCT05717998?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Magnetic Resonance Imaging of the Heart (PROCEDURE).

Who is sponsoring clinical trial NCT05717998?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05717998 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.